Baxter International
BAX
$16.90
-5.80%
Baxter International Inc. is a global healthcare company that manufactures and supplies a broad portfolio of essential medical products, including injectable therapies, IV pumps, nutritional products, surgical sealants, and hospital equipment such as beds and patient monitors. The company operates as a significant, established player in the medical instruments and supplies industry, having expanded its hospital-focused offerings through the acquisition of Hillrom in late 2021. The current investor narrative is dominated by a challenging turnaround story, as the company grapples with significant operational headwinds, including a recent manufacturing disruption affecting a critical cancer drug supply in Europe, disappointing 2026 profit guidance that triggered a sharp stock decline, and broader concerns over input cost inflation from geopolitical tensions impacting petrochemicals.…
BAX
Baxter International
$16.90
Related headlines
Investment Opinion: Should I buy BAX Today?
Rating: Hold. The core thesis is that Baxter is a broken turnaround story where the severe operational risks currently outweigh the deep valuation discount, requiring investors to wait for proof of stabilization before committing capital. This aligns with the prevailing neutral-to-cautious analyst sentiment.
Supporting evidence for this Hold rating includes the stock's deeply discounted PS ratio of 0.87, the positive but insufficient 8.03% revenue growth, the catastrophic negative net margin of -8.5%, and the company's still-positive trailing free cash flow of $323 million. The forward P/E of 8.97 on estimated EPS of $2.22 appears cheap, but those estimates are highly speculative given the recent $1.13 billion quarterly loss. The stock trades just 15.2% above its 52-week low, indicating the market shares this deep skepticism.
The two biggest risks that could invalidate a Hold thesis are 1) a further gross margin decline below the Q4 level of 19.4%, signaling irreversible structural issues, and 2) a deterioration in liquidity, with operating cash flow turning negative. This Hold would upgrade to a Buy if the company demonstrates a clear quarter-over-quarter gross margin recovery back above 30% or provides credible, detailed guidance for achieving its $2.22 EPS target. It would downgrade to a Sell on a breakdown below the $15.73 support level on high volume. Relative to its own battered history and sector peers, the stock is fairly valued for a company in crisis, not undervalued for a healthy one.
Sign up to view all
BAX 12-Month Price Forecast
The AI assessment is neutral based on the high uncertainty surrounding Baxter's ability to execute a turnaround. The catastrophic Q4 results have broken the investment thesis, and the stock's deep valuation discount is a warranted reflection of that crisis, not a clear opportunity. The positive cash flow and liquidity provide a lifeline, but the path to restoring profitability is unclear and fraught with external cost risks. Confidence is medium because the data clearly shows a company in distress, but the outcome is binary: either a successful fix or further decline. The stance would upgrade to bullish only upon concrete, multi-quarter evidence of margin recovery; a single missed quarter or guidance cut would trigger a downgrade to bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Baxter International's 12-month outlook, with a consensus price target around $21.97 and implied upside of +30.0% versus the current price.
Average Target
$21.97
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$14 - $22
Analyst target range
Analyst coverage for Baxter is limited, with only 4 analysts providing estimates, indicating this large-cap stock has fallen out of favor with the broader institutional research community. The consensus sentiment, inferred from recent institutional ratings, is neutral to cautious, with firms like Citigroup and Goldman Sachs maintaining 'Neutral' stances, Barclays at 'Overweight', and Morgan Stanley at 'Underweight'. A notable downgrade occurred in late 2025 when Argus Research moved from 'Buy' to 'Hold'. The lack of a published average target price in the data implies insufficient consensus to calculate a clear upside or downside, reinforcing the theme of low coverage and high uncertainty. The range of analyst expectations is not fully quantifiable from the provided data, but the recent news and guidance suggest a wide dispersion of outcomes. The high-end scenario would require a successful resolution of manufacturing issues, cost inflation management, and a return to historical margin profiles. The low-end scenario, which seems more immediately priced in, factors in continued operational challenges, failed turnaround efforts, and further guidance reductions. The pattern of recent ratings—mostly holds and neutrals following the weak guidance—signals that analysts are in a 'wait-and-see' mode, awaiting concrete signs of operational improvement before turning more bullish. The limited coverage itself is a signal, often associated with stocks experiencing fundamental crises where the investment thesis is broken and requires proof of repair.
Bulls vs Bears: BAX Investment Factors
The evidence currently tilts decisively towards the bear case, as the catastrophic Q4 margin collapse and ongoing operational disruptions represent immediate, quantifiable threats to the company's survival as a profitable entity. While the bull case rests on a deeply discounted valuation and strong liquidity providing a potential floor, these are passive factors that require active operational improvement to unlock value. The single most important tension in the investment debate is whether the Q4 2025 results represent a one-time, fixable operational catastrophe or the unveiling of a structural, unsustainable business model post-Hillrom acquisition. The resolution of this tension—through either a demonstrated margin recovery in upcoming quarters or further deterioration—will dictate the stock's direction.
Bullish
- Deeply Discounted Valuation: The stock trades at a trailing PS ratio of 0.87 and an EV/Sales of 1.54, which are significantly below typical healthcare sector multiples. This extreme discount, from historical PS ratios above 5.0, suggests the market has priced in severe distress, offering a potential margin of safety if operations stabilize.
- Strong Liquidity and Positive Cash Flow: Despite massive losses, the company maintains a robust current ratio of 2.31 and generated $584 million in operating cash flow in Q4 2025. Trailing twelve-month free cash flow of $323 million provides a buffer to service its debt and fund a turnaround.
- Revenue Growth Amidst Crisis: Q4 2025 revenue grew 8.03% year-over-year to $2.97 billion, demonstrating underlying demand for its essential medical products. This growth, while overshadowed by margin collapse, suggests the core business retains customer relevance.
- Oversold Technical Condition: The stock is down 40.28% over the past year and trades just 15.2% above its 52-week low of $15.73, indicating deep pessimism. A low beta of 0.617 suggests it has been less volatile than the market during this decline, which could limit further downside in a broad sell-off.
Bearish
- Catastrophic Margin Collapse: Q4 2025 gross margin collapsed to 19.4% from 33.5% in Q3, driving a net loss of $1.13 billion. This severe, sudden deterioration indicates a fundamental operational breakdown, not a gradual trend, raising serious questions about management's cost control.
- Elevated Financial Leverage: The company's debt-to-equity ratio stands at 1.63, indicating a leveraged balance sheet. This high debt load increases financial risk and limits strategic flexibility, especially while the company is burning through shareholder equity, as shown by the -15.6% ROE.
- Ongoing Operational Disruptions: Recent news highlights a critical cancer drug supply disruption in Europe and warnings of rising petrochemical costs pressuring margins. These are not one-time events but ongoing headwinds that threaten the already-fragile profitability guidance for 2026.
- Broken Investor Narrative and Sentiment: The stock has fallen out of favor, with only 4 analysts providing coverage and recent ratings mostly 'Neutral' or 'Hold'. The 2026 profit guidance miss triggered a sharp sell-off, and the stock's 53.84% max drawdown shows a complete loss of investor confidence.
BAX Technical Analysis
The prevailing price trend for Baxter is a pronounced and sustained downtrend, with the stock down 40.28% over the past year. The current price of $18.16 sits just 15.2% above its 52-week low of $15.73, positioning it near the bottom of its annual range, which signals deep investor pessimism and potential value opportunity, albeit with high risk of further fundamental deterioration. The stock is trading at only 55.6% of its 52-week range, indicating it is deeply oversold relative to its recent history. Recent short-term momentum shows a modest 6.07% gain over the past month, which conflicts sharply with the longer-term downtrend. However, this one-month bounce is dwarfed by the persistent weakness, with the stock still down 8.47% over three months and 21.11% over six months, suggesting the recent uptick is likely a technical rebound within a broader bear market rather than a sustainable reversal. Key technical support is firmly established at the 52-week low of $15.73, while resistance lies at the 52-week high of $32.68. A breakdown below $15.73 would signal a new leg down, while a sustained move above the $20-$21 area is needed to suggest any meaningful recovery is underway. The stock's beta of 0.617 indicates it has been significantly less volatile than the broader market during this decline, which is unusual for a stock under such fundamental pressure and may reflect its large-cap, defensive sector status.
Beta
0.62
0.62x market volatility
Max Drawdown
-53.8%
Largest decline past year
52-Week Range
$16-$33
Price range past year
Annual Return
-45.4%
Cumulative gain past year
| Period | BAX Return | S&P 500 |
|---|---|---|
| 1m | +7.0% | +12.6% |
| 3m | -14.3% | +2.5% |
| 6m | -8.5% | +4.3% |
| 1y | -45.4% | +28.4% |
| ytd | -13.3% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BAX Fundamental Analysis
Baxter's revenue trajectory shows modest growth but is overshadowed by severe profitability issues. The most recent Q4 2025 revenue was $2.97 billion, representing an 8.03% year-over-year increase. However, this growth is not translating to the bottom line, as the company posted a staggering net loss of $1.13 billion for the quarter, driven by a gross margin that collapsed to 19.4% from much higher levels in prior quarters. Segment data indicates Medical Products and Therapies is the largest contributor at $1.39 billion, but overall growth is insufficient to offset margin compression. Profitability and margins have deteriorated catastrophically in the latest quarter. The Q4 2025 net income was -$1.13 billion, with a gross margin of 19.4%, a severe contraction from the 33.5% gross margin reported in Q3 2025. The operating margin was deeply negative at -24.5% for Q4. This follows a volatile pattern through 2025, with Q2 showing a net income of $91 million and a gross margin of 35.3%, indicating the Q4 results represent a significant, company-specific operational breakdown rather than a gradual trend. The balance sheet and cash flow present a mixed picture of financial health. The company maintains a strong current ratio of 2.31, indicating good short-term liquidity. However, the debt-to-equity ratio is elevated at 1.63, signaling a leveraged capital structure. Trailing twelve-month free cash flow is positive at $323 million, and operating cash flow for Q4 2025 was $584 million, providing some capacity to service debt. The negative Return on Equity of -15.6% underscores the profound destruction of shareholder value currently underway due to the massive quarterly loss.
Quarterly Revenue
$3.0B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.19%
Latest Quarter
Free Cash Flow
$323000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BAX Overvalued?
Given Baxter's deeply negative net income and EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio, as earnings-based multiples are not meaningful. The trailing PS ratio is 0.87, while the forward-looking metric, EV-to-Sales, is 1.54. The gap between these suggests the market is ascribing some value to future sales growth or margin recovery, but the multiples remain depressed overall. Compared to industry averages, Baxter's valuation appears discounted. Its PS ratio of 0.87 and EV/Sales of 1.54 are low for the healthcare sector, typically trading at higher sales multiples due to stable cash flows. This significant discount quantifies the market's severe punishment for the company's operational missteps and guidance cut, pricing in substantial uncertainty and skepticism about a near-term turnaround. Historically, Baxter's valuation has compressed dramatically. The current PS ratio of 0.87 is near the bottom of its observable range, a stark contrast to ratios above 5.0 seen in 2023 and early 2024. This precipitous decline from historical highs indicates the market has completely reset expectations, moving from pricing in growth and stability to pricing in distress and restructuring. Trading at these depressed levels suggests the stock is either a deep value opportunity if management can execute a recovery, or appropriately valued for a business facing structural challenges.
PE
-10.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -64x~149x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on profitability. The Q4 2025 gross margin collapse from 33.5% to 19.4% and a $1.13 billion net loss demonstrate an acute operational crisis. While the current ratio of 2.31 is strong, the elevated debt-to-equity of 1.63 creates vulnerability if cash flows weaken further. Revenue, while growing at 8.03% YoY, is insufficient to offset this margin pressure, and the company's valuation is entirely dependent on a successful and rapid turnaround to justify even its depressed sales multiples.
Market & Competitive Risks include valuation compression and external cost pressures. The stock's PS ratio of 0.87 is a dramatic fall from historical highs above 5.0, but could compress further if the turnaround fails. Recent news highlights a direct threat from rising petrochemical costs due to geopolitical tensions, which would further pressure the already-decimated gross margins. Furthermore, the stock's low beta of 0.617 may offer false comfort; its 70.87% underperformance vs. the S&P 500 over the past year shows it faces severe company-specific, not market, risks.
Worst-Case Scenario involves a failed turnaround leading to a liquidity crisis. The chain would be: continued manufacturing issues and cost inflation prevent margin recovery, 2026 guidance is cut again, operating cash flow turns negative, and the leveraged balance sheet forces a dilutive equity raise or debt restructuring. In this scenario, the stock could realistically re-test and break its 52-week low of $15.73. Given the current price of $18.16, this implies a downside of approximately -13%. A more severe bear case, factoring in a potential crisis of confidence, could see the stock fall toward the $12-$14 range, representing a potential loss of 25-35% from current levels.
FAQ
The key risks are, in order of severity: 1) Operational Risk: The inability to restore gross margins from the catastrophic 19.4% level back to historical norms above 30%, which would lead to persistent losses. 2) Financial Risk: The elevated debt-to-equity ratio of 1.63 could become unsustainable if cash flows weaken, potentially leading to dilution or restructuring. 3) External Cost Risk: Rising petrochemical costs, as highlighted in recent news, could apply further pressure on already-decimated margins. 4) Sentiment Risk: With only 4 analysts covering the stock and a history of guidance misses, negative news could trigger another sharp sell-off, as seen with the 53.84% max drawdown.
The 12-month forecast for BAX is a wide range of outcomes with a base-case target of $18-$22 (60% probability). This reflects a messy, protracted recovery where the company avoids another disaster but fails to fully regain investor confidence. The bull case (20% probability) targets $26-$30, requiring a successful and rapid operational turnaround meeting the $2.22 EPS guidance. The bear case (20% probability) targets $12-$16, involving further operational deterioration and a breach of key support levels. The most likely scenario is the base case, as the sudden nature of the Q4 collapse suggests fixes will not be quick or easy, and analyst sentiment remains in a neutral 'wait-and-see' mode.
BAX is fairly valued relative to its current state of distress, but deeply undervalued relative to its historical norm and sector peers if a recovery occurs. The trailing PS ratio of 0.87 and EV/Sales of 1.54 are low for the healthcare sector, reflecting the market's severe punishment for operational failure. Historically, Baxter traded at PS ratios above 5.0, illustrating how far expectations have fallen. The valuation implies the market expects continued poor profitability or further deterioration. The forward P/E of 8.97 appears cheap but is based on a highly uncertain $2.22 EPS estimate. Therefore, the stock is not obviously undervalued without proof of a turnaround.
BAX is not a good buy for most investors at this time. It is a speculative turnaround bet with a broken thesis, as evidenced by the catastrophic Q4 2025 net loss of $1.13 billion and gross margin collapse to 19.4%. While the stock trades at a deep discount with a PS ratio of 0.87 and has 13% upside to its 52-week high, the downside risk to the $15.73 low (or lower) is significant if operations do not improve. It could only be considered a good buy for highly risk-tolerant, deep-value investors who have done extensive due diligence and are willing to wait potentially years for a recovery, with the understanding that total loss of capital is a real possibility.
BAX is unsuitable for short-term trading due to its low beta (0.617) and broken momentum, which limit volatility-based gains, and the high uncertainty around quarterly results. It is only suitable for a very long-term, patient investment horizon of 3-5 years, if at all. A successful turnaround of this magnitude will require multiple quarters, if not years, of execution. The stock offers a 3.5% dividend yield, but the negative payout ratio indicates it is not sustainable from earnings. Given the speculative nature of the bet, investors must be prepared to hold through significant volatility and potential further downside while awaiting evidence of fundamental repair.